revenue has been held up because there are multiple first to...

revenue has been held up because there are multiple first to file candidates for Jublia generic. I was wrong in my thinking that "first to file" was actually the first. It's not. First to file I now realize is all those who filed on the first day that an application can be made. The hold up is that each applicant all have to go through the Hatch-Waxman act. I have since read that there may be some 13 first to file applicants but have so far only found 9 (including Acrux) that have completed this process. - So I'm wrong but happy to be partially wrong than completely wrong. that still leads to the most important question, what is the real value of Acrux ? there some millions in cash, 34 odd millions spent in research, the value to investors of the PDF structure, to be able to approach large pharma companies with a product and not be fobbed off, the future value of ACR065 IP, the growing cash being generated by the HRT product in Europe. Add to the fact the company has zero debt. the Value is surly higher that the current market cap. Before the Axrion implosion the company was spinning off a lot of cash. High ROE, High Markup, High Profit Margins. the question then was, "is the Axrion implosion terminal or not" ? Seeing how management started the Generic strategy before the Axrion troubles and noticing that strategy has not changed in the intervening years I don't think it's terminal. In fact I believe that with the strategy to file 3-4 products per year and to constantly keep up to 11 products in development it's a potential future ongoing growth company